# Molecular Signatures of Cutaneous Dupilumab Response

> **NCT05858619** · PHASE4 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 15 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT05858619
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858619, "Molecular Signatures of Cutaneous Dupilumab Response". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05858619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*